Results 181 to 190 of about 260,831 (351)
Gut microbiota and risk of heart failure in European population—A comprehensive Mendelian randomization study
ESC Heart Failure, EarlyView.Abstract Aims
Gut dysbiosis is proven to be involved in the pathogenesis and progression of heart failure (HF). Hindering the detrimental effects of gut‐heart axis is an emerging trend. Our goal is to investigate the causal relationship between gut microbiota and HF, with the aim of facilitating future exploration of microbiome‐targeted approaches to ...Liyan Huang, Xuemei Zhao, Jing Wang, Jingyuan Guan, Boping Huang, Jiayu Feng, Xinqing Li, Yuhui Zhang, Jian Zhang +8 morewiley +1 more sourceOrganismal, genetic, and transcriptional variation in the deeply sequenced gut microbiomes of identical twins
, 2010 Peter J. Turnbaugh, Christopher Quince, Jeremiah J. Faith, Alice C. McHardy, Tanya Yatsunenko, Faheem Niazi, Jason P. Affourtit, Michael D. Miller, Bernard Henrissat, Rob Knight, Jeffrey I. Gordon +10 moreopenalex +1 more sourceMETAB‐HTX: prospective, longitudinal cohort study evaluating cardiac and systemic metabolism after heart transplantation
ESC Heart Failure, EarlyView.The METAB‐HTX trial is a prospective cohort study, evaluating cardiac and systemic metabolism among heart transplant recipients. Myocardial function, energetic and metabolism, allograft vasculopathy, allograft rejection, glucometabolism, lipometabolism, liver‐ and kidney function, leucocyte signatures and thromboinflammation will be evaluated ...Amin Polzin, Daniel Scheiber, Fabian Voss, Jean Haurand, Elric Zweck, Daniel Oehler, Oliver Maier, Mareike Cramer, Maximilian Spieker, Constanze Moos, Ursala Tokhi, David Naguib, Philipp Mourikis, Marcel Benkhoff, Robert Wagner, Michael Roden, Heinz‐Peter Schultheiss, Sascha Dietrich, Hug Aubin, Udo Boeken, Artur Lichtenberg, Malte Kelm +21 morewiley +1 more sourceCurrent and novel biomarkers in cardiogenic shock
European Journal of Heart Failure, EarlyView.A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end‐organ dysfunction.Victor Galusko, Florian A. Wenzl, Christophe Vandenbriele, Vasileios Panoulas, Thomas F. Lüscher, Diana A. Gorog +5 morewiley +1 more sourceW1832 Diversity in Human Gut Microbiome Composition Assessed by Pyrosequencing: Comparison of Sampling Methods
, 2010 James D. Lewis, Gary D. Wu, Yingyu Chen, Christian Hoffmann, Kyle Bittinger, Sue A. Keilbaugh, Lisa Nessel, Ronald W. Berkowsky, Jun Chen, Hongzhe Li, Frederic D. Bushman +10 moreopenalex +1 more sourceUpdate on preclinical models of cancer therapy‐related cardiac dysfunction: Challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio‐Oncology, and the ESC Working Group on Cellular Biology of the Heart
European Journal of Heart Failure, EarlyView.New anticancer therapies with potential cardiovascular side effects are continuously being introduced into clinical practice, with new and often unexpected toxicities becoming apparent only after clinical introduction. These unknown toxicities should be identified and understood beforehand to better prepare patients and physicians, enabling the ...Alessandra Ghigo, Pietro Ameri, Aarti Asnani, Edoardo Bertero, Rudolf A. de Boer, Dimitrios Farmakis, Arantxa González, Stephane Heymans, Borja Ibáñez, Teresa López‐Fernández, Alexander R. Lyon, Piero Pollesello, Amina Rakisheva, Konstantinos Stellos, Katrin Streckfuss‐Bömeke, Carlo Gabriele Tocchetti, Thomas Thum, Peter van der Meer, Eva Van Rooij, Piotr Ponikowski, Marco Metra, Giuseppe Rosano, Sophie Van Linthout +22 morewiley +1 more sourceThe crosstalk between immune activation and metabolism in heart failure. A scientific statement of the Heart Failure Association of the ESC
European Journal of Heart Failure, EarlyView.Abstract
A better understanding of additional mechanisms of heart failure (HF) progression may allow a different and more complete phenotyping of the disease and identification of novel therapeutic targets. Persistent latent myocardial inflammation/immune activation in HF may represent an attempt to restore tissue homeostasis in the failing heart ...Gabriele Fragasso, Davide Stolfo, Markus S. Anker, Antoni Bayes‐Genis, Ovidiu Chioncel, Stephane Heymans, Pardeep S. Jhund, Basil S. Lewis, Gary D. Lopaschuk, Lars H. Lund, Arantxa Gonzalez, Matteo Pagnesi, Gabriele Giacomo Schiattarella, Carlo Gabriele Tocchetti, Peter van der Meer, Sophie Von Linthout, Sven Wassmann, B. Daan Westenbrink, Marco Metra, Giuseppe M.C. Rosano, Gianluigi Savarese +20 morewiley +1 more source